RESUMEN
Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class that is being evaluated in clinical trials. To improve the antibacterial activity and pharmacokinetic properties of ETX0914, we carried out systematic structural modification of this compound, and a number of compounds with increased potency were obtained. The most promising compound 33e, with incorporation of a spirocyclopropane at the oxazolidinone 5 position reduced metabolism, exhibited excellent antibacterial activity against Gram-positive pathogens and a good pharmacokinetic profile combined with high aqueous solubility. In addition, compound 33e exhibited good selectivity for Staphylococcus aureus gyrase over human Topo IIα. In a murine model of systemic methicillin-resistant S. aureus infection, 33e exhibited superior in vivo efficacy (ED50 = 3.87 mg/kg) compared to ETX0914 (ED50 = 11.51 mg/kg).
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacología , Girasa de ADN/efectos de los fármacos , Diseño de Fármacos , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Compuestos de Espiro/química , Compuestos de Espiro/farmacología , Inhibidores de Topoisomerasa II/química , Inhibidores de Topoisomerasa II/farmacología , Animales , Antibacterianos/farmacocinética , Perros , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Infecciones por Bacterias Grampositivas/microbiología , Humanos , Ratones , Pruebas de Sensibilidad Microbiana , Ratas , Compuestos de Espiro/farmacocinética , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II/farmacocinéticaRESUMEN
Artesunate (AS), a semisynthetic artemisinin approved for malaria therapy, inhibits human cytomegalovirus (HCMV) replication in vitro, but therapeutic success in humans has been variable. We hypothesized that the short in vivo half-life of AS may contribute to the different treatment outcomes. We tested novel synthetic ozonides with longer half-lives against HCMV in vitro and mouse cytomegalovirus (MCMV) in vivo Screening of the activities of four ozonides against a pp28-luciferase-expressing HCMV Towne recombinant identified OZ418 to have the best selectivity; its effective concentration inhibiting viral growth by 50% (EC50) was 9.8 ± 0.2 µM, and cytotoxicity in noninfected human fibroblasts (the concentration inhibiting cell growth by 50% [CC50]) was 128.1 ± 8.0 µM. In plaque reduction assays, OZ418 inhibited HCMV TB40 in a concentration-dependent manner as well as a ganciclovir (GCV)-resistant HCMV isolate. The combination of OZ418 and GCV was synergistic in HCMV inhibition in vitro Virus inhibition by OZ418 occurred at an early stage and was dependent on the cell density at the time of infection. OZ418 treatment reversed HCMV-mediated cell cycle progression and correlated with the reduction of HCMV-induced expression of pRb, E2F1, and cyclin-dependent kinases 1, 2, 4, and 6. In an MCMV model, once-daily oral administration of OZ418 had significantly improved efficacy against MCMV compared to that of twice-daily oral AS. A parallel pharmacokinetic study with a single oral dose of OZ418 or AS showed a prolonged plasma half-life and higher unbound concentrations of OZ418 than unbound concentrations of AS. In summary, ozonides are proposed to be potential therapeutics, alone or in combination with GCV, for HCMV infection in humans.
Asunto(s)
Antivirales/farmacología , Infecciones por Citomegalovirus/tratamiento farmacológico , Citomegalovirus/efectos de los fármacos , Compuestos Heterocíclicos con 1 Anillo/farmacología , Interacciones Huésped-Patógeno/efectos de los fármacos , Compuestos de Espiro/farmacología , Replicación Viral/efectos de los fármacos , Animales , Antivirales/sangre , Antivirales/química , Antivirales/farmacocinética , Proteína Quinasa CDC2/genética , Proteína Quinasa CDC2/metabolismo , Línea Celular , Citomegalovirus/genética , Citomegalovirus/metabolismo , Infecciones por Citomegalovirus/virología , Esquema de Medicación , Evaluación Preclínica de Medicamentos , Farmacorresistencia Viral/efectos de los fármacos , Farmacorresistencia Viral/genética , Factor de Transcripción E2F1/genética , Factor de Transcripción E2F1/metabolismo , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/patología , Fibroblastos/virología , Ganciclovir/farmacología , Regulación de la Expresión Génica , Compuestos Heterocíclicos con 1 Anillo/sangre , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Proteína de Retinoblastoma/genética , Proteína de Retinoblastoma/metabolismo , Transducción de Señal , Compuestos de Espiro/sangre , Compuestos de Espiro/química , Compuestos de Espiro/farmacocinéticaRESUMEN
With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-one derivatives, which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model. Among the compounds synthesized, compound 4d showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concentration in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats. Furthermore, 4d exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration. These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.
Asunto(s)
ATPasa Intercambiadora de Hidrógeno-Potásio/metabolismo , Piperidinas/química , Potasio/metabolismo , Inhibidores de la Bomba de Protones/síntesis química , Compuestos de Espiro/química , Administración Intravenosa , Animales , Área Bajo la Curva , Sitios de Unión , Evaluación Preclínica de Medicamentos , Ácido Gástrico/metabolismo , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , ATPasa Intercambiadora de Hidrógeno-Potásio/química , Semivida , Histamina/toxicidad , Concentración 50 Inhibidora , Simulación del Acoplamiento Molecular , Naftalenos/química , Piperidinas/síntesis química , Piperidinas/farmacocinética , Potasio/química , Inhibidores de la Bomba de Protones/química , Inhibidores de la Bomba de Protones/farmacocinética , Curva ROC , Ratas , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacocinética , Relación Estructura-ActividadRESUMEN
The MIC of an antimalarial drug for a particular infection is the drug level associated with a net parasite multiplication rate of one per asexual cycle. To ensure the cure of malaria, the MIC must be exceeded until all parasites have been eliminated. The development of highly sensitive and accurate PCR quantitation of low-density malaria parasitemia enables the prospective pharmacokinetic-pharmacodynamic (PK-PD) characterization of antimalarial drug effects and now allows identification of the in vivo MIC. An adaptive design and a PK-PD modeling approach were used to determine prospectively the MIC of the new antimalarial cipargamin (KAE609) in adults with uncomplicated Plasmodium falciparum malaria in an open-label, dose-ranging phase 2a study. Vietnamese adults with acute P. falciparum malaria were allocated sequentially to treatment with a single 30-mg (n = 6), 20-mg (n = 5), 10-mg (n = 7), or 15-mg (n = 7) dose of cipargamin. Artemisinin-based combination therapy was given after parasite densities had fallen and then risen as cipargamin levels declined below the MIC but before a return of signs or symptoms. The rates of parasite clearance were dose dependent, with near saturation of the effect being seen at an adult dose of 30 mg. The developed PK-PD model accurately predicted the therapeutic responses in 23/25 patients. The predicted median in vivo MIC was 0.126 ng/ml (range, 0.038 to 0.803 ng/ml). Pharmacometric characterization of the relationship between antimalarial drug concentrations and parasite clearance rates following graded subtherapeutic antimalarial drug dosing is safe and provides a rational framework for dose finding in antimalarial drug development. (This study has been registered at ClinicalTrials.gov under identifier NCT01836458.).
Asunto(s)
Antimaláricos/farmacocinética , Antimaláricos/uso terapéutico , Indoles/farmacocinética , Indoles/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/metabolismo , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/uso terapéutico , Adulto , Antimaláricos/efectos adversos , Pueblo Asiatico , Humanos , Indoles/efectos adversos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Compuestos de Espiro/efectos adversos , Adulto JovenRESUMEN
A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-ß peptide (Aß) concentrations, plays a key role in the pathogenesis of Alzheimer's disease (AD). Beta-secretase 1 (BACE1) mediates the first step in the processing of amyloid-ß protein precursor (AßPP) to Aß peptides, with the soluble N terminal fragment of AßPP (sAßPPß) as a direct product, and BACE1 inhibition is an attractive target for therapeutic intervention to reduce the production of Aß. Here, we report the in vitro and in vivo pharmacological profile of AZD3293, a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics. The in vitro potency of AZD3293 was demonstrated in several cellular models, including primary cortical neurons. In vivo in mice, guinea pigs, and dogs, AZD3293 displayed significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aß40, Aß42, and sAßPPß. The in vitro potency of AZD3293 in mouse and guinea pig primary cortical neuronal cells was correlated to the in vivo potency expressed as free AZD3293 concentrations in mouse and guinea pig brains. In mice and dogs, the slow off-rate from BACE1 may have translated into a prolongation of the observed effect beyond the turnover rate of Aß. The preclinical data strongly support the clinical development of AZD3293, and patients with AD are currently being recruited into a combined Phase 2/3 study to test the disease-modifying properties of AZD3293.
Asunto(s)
Secretasas de la Proteína Precursora del Amiloide/antagonistas & inhibidores , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacocinética , Imidazoles/administración & dosificación , Imidazoles/farmacocinética , Compuestos de Espiro/administración & dosificación , Compuestos de Espiro/farmacocinética , Administración Oral , Péptidos beta-Amiloides/metabolismo , Animales , Análisis Químico de la Sangre , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/enzimología , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Cobayas , Humanos , Cinética , Masculino , Ratones Endogámicos C57BL , Fragmentos de Péptidos/metabolismoRESUMEN
CEP-32215 is a new, potent, selective, and orally bioavailable inverse agonist of the histamine H3 receptor (H3R) with drug-like properties. High affinity in human (hH3R Ki = 2.0 ± 0.2 nM) and rat (rH3R Ki = 3.6 ± 0.7 nM) H3R radioligand binding assays was demonstrated. Potent functional antagonism (Kb = 0.3 ± 0.1 nM) and inverse agonism (EC50 = 0.6 ± 0.2 nM) were demonstrated in [(35)S]guanosine 5(')-O-(γ-thio)-triphosphate binding assays. Oral bioavailability and dose-related exposure was consistent among rat, dog, and monkey. After oral dosing, occupancy of H3R by CEP-32215 was estimated by the inhibition of ex vivo binding in rat cortical slices (ED50 = 0.1 mg/kg p.o.). Functional antagonism in brain was demonstrated by the inhibition of R-α-methylhistamine-induced drinking in the rat dipsogenia model (ED50 = 0.92 mg/kg). CEP-32215 significantly increased wake duration in the rat EEG model at 3-30 mg/kg p.o. Increased motor activity, sleep rebound or undesirable events (such as spike wave or seizure activity) was not observed following doses up to 100 mg/kg p.o., indicating an acceptable therapeutic index. CEP-32215 may have potential utility in the treatment of a variety of sleep disorders. This article is part of the Special Issue entitled 'Histamine Receptors'.
Asunto(s)
Agonismo Inverso de Drogas , Antagonistas de los Receptores Histamínicos H3/farmacología , Piperidinas/farmacología , Pirazinas/farmacología , Compuestos de Espiro/farmacología , Vigilia/efectos de los fármacos , Administración Oral , Animales , Disponibilidad Biológica , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Perros , Ingestión de Líquidos/efectos de los fármacos , Ingestión de Líquidos/fisiología , Evaluación Preclínica de Medicamentos , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Humanos , Macaca fascicularis , Masculino , Metilhistaminas/farmacología , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Piperidinas/farmacocinética , Pirazinas/farmacocinética , Ratas Sprague-Dawley , Receptores Histamínicos H3/metabolismo , Sueño/efectos de los fármacos , Sueño/fisiología , Compuestos de Espiro/farmacocinética , Vigilia/fisiologíaRESUMEN
INTRODUCTION: Pharmacologic maintenance of normoglycemia in diabetes cannot prevent the eventual complications mainly due to protein glycation-induced cell death, dysregulated antioxidant defense and signal transduction in affected tissues. The rate-limiting enzyme of this process, aldose reductase, is therefore a pharmacologic target. To date, nine inhibitors of this enzyme have been developed. Ranirestat has completed two Phase III clinical trials. The objective of this evaluation is to summarize and provide expert opinion on the status of ranirestat with an emphasis on its pharmacokinetics in the context of its potential effects to prevent/treat diabetic complications. AREAS COVERED: A qualitative systematic literature search of PubMed through November 2013 using MeSH terms - aldose reductase inhibitors, diabetic neuropathy, AS-3201, ranirestat, diabetic complications and pharmacokinetics/pharmacodynamics - identified relevant publications limited to human and rodent (mouse and rat) and English-language studies. EXPERT OPINION: Ranirestat is a well-tolerated front-line inhibitor. It reproducibly exhibits some degree of measurable objective beneficial outcomes in diabetic neuropathy. It is the furthest advanced in clinical trials with some depth of supporting preclinical data. Trials in subjects with newly diagnosed neuropathy along with the identification of objective biomarkers/measurements of efficacy will be critical in identifying the real value and effect of ranirestat.
Asunto(s)
Neuropatías Diabéticas/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , Pirazinas/uso terapéutico , Compuestos de Espiro/uso terapéutico , Aldehído Reductasa/antagonistas & inhibidores , Animales , Biomarcadores/metabolismo , Ensayos Clínicos como Asunto , Neuropatías Diabéticas/fisiopatología , Neuropatías Diabéticas/prevención & control , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/farmacología , Humanos , Ratones , Pirazinas/farmacocinética , Pirazinas/farmacología , Ratas , Reproducibilidad de los Resultados , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/farmacologíaRESUMEN
Stemonae Radix (Stemona tuberosa Lour, Bai Bu) is an important traditional Chinese medicinal (TCM) plant known for its antitussive activity. Croomine, neotuberostemonine and tuberostemonine alkaloids of Stemonae Radix are major components responsible for antitussive action. In this work, plasma pharmacokinetic and biodistribution characteristics of the three alkaloids after oral administration of Stemonae Radix are investigated using a rapid and sensitive UPLC-Q-TOF-HDMS method. Mass spectrometry (MS) was performed on a Waters Micromass high-definition technology with an electrospray ionization source in positive ion mode, with excellent MS mass accuracy and enhanced MS data acquisition. Separation of main alkaloids was achieved on a Waters BEH C(18) column by linear gradient elution. Data were analyzed and estimated by compartmental methods and pharmacokinetic parameters calculated using WinNonlin Professional version 5.1. It was found that croomine, neotuberostemonine and tuberostemonine had faster absorbed into the bloodstream, maintain the high plasma concentration, and pose a large AUC value. The biodistribution of neotuberostemonine and tuberostemonine showed that the higher levels were in liver, and lung. Croomine was discovered in brain and showed that it could cross the blood-brain barrier, indicating that croomine plays an antitussive effect as acting on the central nervous system. Neotuberostemonine and tuberostemonine were not discovered in brain, demonstrating that they play an antitussive effect as peripheral antitussive. This work suggests that the pharmacokinetics and biodistribution based-UPLC-Q-TOF-HDMS can provide a reliable tools for screening bioactive components contributing to pharmacological effects of medicinal herbs.
Asunto(s)
Alcaloides/farmacocinética , Cromatografía Liquida/métodos , Lactonas/farmacocinética , Pirrolidinas/farmacocinética , Compuestos de Espiro/farmacocinética , Stemonaceae/química , Espectrometría de Masas en Tándem/métodos , Administración Oral , Alcaloides/sangre , Alcaloides/química , Animales , Área Bajo la Curva , Semivida , Lactonas/sangre , Lactonas/química , Masculino , Medicina Tradicional China , Estructura Molecular , Raíces de Plantas/química , Pirrolidinas/sangre , Pirrolidinas/química , Ratas , Ratas Wistar , Compuestos de Espiro/sangre , Compuestos de Espiro/química , Distribución TisularRESUMEN
UNLABELLED: In previous years, several publications have reported cases of infants presenting neurological and gastrointestinal symptoms after ingestion of star anise tea. Such teas are sometimes given in various cultures for the treatment of infant colic pains. In most cases, the cause of intoxication was contamination of Chinese star anise (Illicium verum) by Japanese star anise (Illicium anisatum). Indeed, the toxicity of Illicium anisatum, also known as Shikimi, is caused by its content in potent neurotoxins (anisatin, neoanisatin, and pseudoanisatin), due to their activity as non-competitive antagonists of GABA receptors. The main reasons explaining the frequent contaminations are the strong macroscopic resemblance of the 2 substances, as well as the fact that the fruits are often sold partially broken or in ground form. Therefore, in most cases, chemical analysis is required to determine the possible adulterations. CASE REPORT: A 2-month-old infant, in good general health, was brought to the emergency unit after 3 consecutive episodes of central cyanosis and tetany of the limbs with spontaneous recovery the same afternoon. The child was also very irritable, regurgitated a lot, and positioned himself in opisthotonos. Between these episodes, the neurological exam showed some perturbations (horizontal nystagmus and Bell's phenomenon, hypertony of the extensor muscles, and mild hypotony of the axial flexor muscles) with slow improvement over the following hours. The remaining clinical exam, the laboratory work (complete blood count, renal, hepatic, and muscular tests, capillary blood gas, plasmatic amino acids, and urinary organic acids), and the electroencephalogram findings were all normal. In the course of a detailed interview, the parents reported having given 3 bottles to their child, each one containing 200 mL of an infusion with 4 to 5 fruits of star anise, in the hours preceding the symptoms to relieve colic pains. The last seizure-like event took place approximately 8h after the last ingestion. We could prove the ingestion of anisatin, the toxic substance found in Japanese star anise, and the contamination of Chinese star anise by the Japanese species. Indeed, the anisatin analysis by liquid chromatography and mass spectroscopy (LC-MS) in a urine sample taken 22 h after the last infusion ingestion showed trace amounts of the substance. In another urine sample taken 33 h after ingestion, no anisatin could be detected. Furthermore, the analysis of the fruit sample gave an anisatin concentration of 7800 µg/kg while the maximum tolerance value in Switzerland is 1000 µg/kg. CONCLUSION: The evaluation of ALTE in infants should always include the possibility of intoxication. Star anise is generally considered a harmless medicine. Nevertheless, it can sometimes cause a severe intoxication resulting in various neurological and gastrointestinal symptoms. To prevent such events, not only the parents, but also the care personnel and pharmacists must be informed about the possible adverse effects caused either by the overdose of Chinese star anise or by the eventual contamination of herbal teas with Japanese star anise. A better control of the substances by the health authorities is also necessary.
Asunto(s)
Bebidas/toxicidad , Cianosis/inducido químicamente , Illicium/toxicidad , Extractos Vegetales/toxicidad , Tetania/inducido químicamente , Cólico/tratamiento farmacológico , Cromatografía de Gases y Espectrometría de Masas , Humanos , Lactante , Lactonas/farmacocinética , Lactonas/toxicidad , Masculino , Tasa de Depuración Metabólica/fisiología , Examen Neurológico/efectos de los fármacos , Neurotoxinas/farmacocinética , Fototerapia , Sesquiterpenos/farmacocinética , Sesquiterpenos/toxicidad , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/toxicidadRESUMEN
We have continued to explore spirobenzazepines as vasopressin receptor antagonists to follow up on RWJ-339489 (2), which had advanced into preclinical development. Further structural modifications were pursued to find a suitable backup compound for human clinical studies. Thus, we identified carboxylic acid derivative 3 (RWJ-676070; JNJ-17158063) as a potent, balanced vasopressin V(1a)/V(2) receptor antagonist with favorable properties for clinical development. Compound 3 is currently undergoing human clinical investigation.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas , Benzazepinas/química , Compuestos de Espiro/química , Animales , Antihipertensivos/administración & dosificación , Antihipertensivos/química , Antihipertensivos/metabolismo , Antihipertensivos/farmacocinética , Benzazepinas/administración & dosificación , Benzazepinas/farmacocinética , Benzazepinas/farmacología , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Masculino , Ratas , Ratas Long-Evans , Receptores de Vasopresinas/metabolismo , Receptores de Vasopresinas/fisiología , Compuestos de Espiro/administración & dosificación , Compuestos de Espiro/metabolismo , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/farmacología , Vasopresinas/metabolismoRESUMEN
A series of N-substituted analogs based upon the spiropiperidine core of 1 was synthesized and exhibited high binding affinity to the nociceptin (NOP) receptor. The selectivities against other known opioid receptors were determined.
Asunto(s)
Piperidinas/síntesis química , Receptores Opioides/agonistas , Administración Oral , Animales , Tos/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Guanosina 5'-O-(3-Tiotrifosfato) , Ligandos , Farmacocinética , Piperidinas/farmacocinética , Piperidinas/farmacología , Unión Proteica , Ratas , Receptores Opioides/metabolismo , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/farmacología , Relación Estructura-Actividad , Receptor de NociceptinaRESUMEN
Ranirestat is an orally available aldose reductase inhibitor under development by Dainippon Sumitomo Pharma Co Ltd (formerly Dainippon Pharmaceutical Co Ltd), Kyorin Pharmaceutical Co Ltd and Eisai Co Ltd for the potential treatment of diabetic complications, such as neuropathy, cataracts, retinopathy and nephropathy. Phase III trials were ongoing in February 2006.
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Complicaciones de la Diabetes/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , Pirazinas/uso terapéutico , Compuestos de Espiro/uso terapéutico , Animales , Ensayos Clínicos Fase II como Asunto , Ensayos Clínicos Fase III como Asunto , Contraindicaciones , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacocinética , Humanos , Pirazinas/efectos adversos , Pirazinas/metabolismo , Pirazinas/farmacocinética , Compuestos de Espiro/efectos adversos , Compuestos de Espiro/metabolismo , Compuestos de Espiro/farmacocinética , Relación Estructura-ActividadRESUMEN
The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which--the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)--may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.
Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Artemisininas/química , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Compuestos Heterocíclicos con 1 Anillo/síntesis química , Compuestos Heterocíclicos con 1 Anillo/farmacología , Peróxidos , Sesquiterpenos/química , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacología , Animales , Antimaláricos/química , Antimaláricos/farmacocinética , Disponibilidad Biológica , Semivida , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Humanos , Concentración 50 Inhibidora , Malaria/tratamiento farmacológico , Malaria/metabolismo , Malaria/parasitología , Ratones , Oxidación-Reducción , Plasmodium berghei/efectos de los fármacos , Plasmodium berghei/fisiología , Plasmodium falciparum/efectos de los fármacos , Ratas , Ratas Wistar , Solubilidad , Compuestos de Espiro/química , Compuestos de Espiro/farmacocinética , Distribución TisularRESUMEN
RATIONALE: The possible role of compensatory changes in 5-HT2C receptors in the reduced hypophagic action of d-fenfluramine in 5-HT1B knockout (KO) mice was assessed by comparing their response to d-fenfluramine and the 5-HT2C receptor agonist mCPP. In addition we measured 5-HT(2C/A) receptor binding in 5-HT1B KO and wild-type (WT) mice and examined the effects of 5-HT1B receptor antagonists on d-fenfluramine-induced hypophagia in WT mice. METHODS: Hypophagic responses to d-fenfluramine (1-30 mg/kg) and mCPP (1-5.6 mg/kg) were measured using a behavioural satiety sequence paradigm. The effects of the 5-HT1B receptor antagonists GR 127,935 and SB 224289 in opposing the hypophagic action of d-fenfluramine were evaluated in WT mice. The binding of [3H]-mesulergine was compared in the brains of both mouse strains. RESULTS: The hypophagic effects of moderate doses of d-fenfluramine and mCPP were attenuated in 5-HT1B KO mice. Pretreatment of WT mice with the 5-HT(1B/1D) receptor antagonist GR 127,935, or food-deprived WT mice with the 5-HT1B receptor antagonist SB 224289, did not reproduce the reduction in sensitivity to the effects of d-fenfluramine on feeding behaviour observed in 5-HT1B KO mice. Estimates of 5-HT2C receptor binding were similar in 5-HT1B KO and WT mice. CONCLUSIONS: The hypophagic effect of d-fenfluramine in mice is unlikely to be mediated by the 5-HT1B receptor. Instead, the evidence suggests that an adaptive change in 5-HT2C receptor function occurs in 5-HT1B receptor KO mice and contributes to their reduced response to d-fenfluramine.
Asunto(s)
Fenfluramina/farmacocinética , Ratones Noqueados/genética , Piperazinas/farmacocinética , Receptor de Serotonina 5-HT1B/deficiencia , Receptor de Serotonina 5-HT1B/genética , Saciedad/efectos de los fármacos , Agonistas del Receptor de Serotonina 5-HT2 , Animales , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Corteza Cerebral/ultraestructura , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Evaluación Preclínica de Medicamentos/métodos , Ingestión de Alimentos/efectos de los fármacos , Ergolinas/administración & dosificación , Ergolinas/farmacocinética , Fenfluramina/administración & dosificación , Genotipo , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Isomerismo , Mianserina/farmacología , Ratones , Piperazinas/administración & dosificación , Piperidonas/administración & dosificación , Piperidonas/farmacocinética , Receptor de Serotonina 5-HT2A , Receptor de Serotonina 5-HT2C/administración & dosificación , Saciedad/fisiología , Respuesta de Saciedad/efectos de los fármacos , Respuesta de Saciedad/fisiología , Especificidad de la Especie , Espiperona/farmacología , Compuestos de Espiro/administración & dosificación , Compuestos de Espiro/farmacocinética , Factores de Tiempo , Tritio , Reino UnidoRESUMEN
On the basis of a spirocyclic ether screening lead, a series of acyclic sulfones have been identified as high-affinity, selective 5-HT(2A) receptor antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-difluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine (12), was introduced by using stability toward rat liver microsomes as a predictor of bioavailability. By this means, the 4-cyano- and 4-carboxamidophenylsulfonyl derivatives 26 and 31 were identified as orally bioavailable, brain-penetrant analogues suitable for evaluation in animal models. Bioavailability was also attainable by N substitution leading to the N-phenacyl derivative 35. IKr activity detected through counterscreening was reduced to insignificant levels in vivo with the latter compound.
Asunto(s)
Benzamidas/síntesis química , Proteínas de Transporte de Catión , Proteínas de Unión al ADN , Nitrilos/síntesis química , Piperidinas/síntesis química , Canales de Potasio con Entrada de Voltaje , Receptores de Serotonina/efectos de los fármacos , Antagonistas de la Serotonina/síntesis química , Compuestos de Espiro/síntesis química , Sulfonas/síntesis química , Transactivadores , Administración Oral , Animales , Benzamidas/química , Benzamidas/farmacocinética , Benzamidas/farmacología , Disponibilidad Biológica , Encéfalo/metabolismo , Línea Celular , Cricetinae , Evaluación Preclínica de Medicamentos , Canal de Potasio ERG1 , Electrocardiografía , Canales de Potasio Éter-A-Go-Go , Hurones , Humanos , Técnicas In Vitro , Masculino , Microsomas Hepáticos/metabolismo , Nitrilos/química , Nitrilos/farmacocinética , Nitrilos/farmacología , Piperidinas/química , Piperidinas/farmacocinética , Piperidinas/farmacología , Canales de Potasio/metabolismo , Canales de Potasio/fisiología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2A , Antagonistas de la Serotonina/química , Antagonistas de la Serotonina/farmacocinética , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/síntesis química , Agonistas de Receptores de Serotonina/química , Agonistas de Receptores de Serotonina/farmacocinética , Agonistas de Receptores de Serotonina/farmacología , Compuestos de Espiro/química , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/farmacología , Relación Estructura-Actividad , Sulfonas/química , Sulfonas/farmacocinética , Sulfonas/farmacología , Regulador Transcripcional ERGRESUMEN
The applicability of alpha-tocopherol as a lymphotropic carrier for a highly lipophilic drug has been evaluated. Transport to the intestinal lymph of the highly lipophilic model drug, Lu28-179, in rats after administration to the stomach in an alpha-tocopherol emulsion was compared with lymphatic transport after administration of a sesame oil emulsion and an alpha-tocopherol/sesame oil emulsion. Lymphatic transport of the triglycerides and of alpha-tocopherol was determined. A conscious rat model was used, and the mesenteric lymph was collected. There was no significant difference between the cumulative masses of triglyceride from the two emulsions containing triglyceride 24 h after administration. Administration of an alpha-tocopherol emulsion seemed to induce mobilization of endogenous triglyceride. The lymphatic transport of alpha-tocopherol was less than 1 mg 24 h after administration of both emulsions containing alpha-tocopherol. The absorption of Lu28-179 from the alpha-tocopherol emulsion was very low, with a lymphatic recovery of 0.05%. When administered in an alpha-tocopherol/sesame oil emulsion, the recovery of Lu28-179 increased sevenfold to 0.35%. However, after administration of Lu28-179 in a sesame oil emulsion, the lymphatic recovery increased a further 13-fold to 4.5%. In conclusion, the study showed that alpha-tocopherol did not promote lymphatic absorption of Lu28-179 and thus was not a good lymphotropic carrier, as compared with sesame oil. Alpha-tocopherol in combination with sesame oil was not a good lymphotropic carrier either. The non-absorbed alpha-tocopherol fraction in the intestine might be able to prevent the absorption of Lu28-179.